All In Biotech

Drug Trial Radar · NCT01964378

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

Efficacy, Safety, and Tolerability of Oral Cebranopadol Versus Morphine Sulfate PR in Subjects With Chronic Moderate to Severe Pain Related to Cancer.

Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

200

Actual

Start

Oct 29, 2013

Primary completion

Oct 16, 2015

Study completion Oct 16, 2015

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
First posted
Oct 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pain is one of the most common symptoms associated with malignant tumor. The purpose of this trial is to determine whether cebranopadol is as effective in patients with cancer related pain as morphine sulfate prolonged release (PR).

Conditions

  • Pain
  • Neoplasms
  • Chronic Pain

Interventions

  • CebranopadolDrug

    Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.

  • Morphine Prolonged ReleaseDrug

    Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Per Protocol Set)Time frame: The last 2 weeks of the expected 6-week treatment period.
  2. Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Full Analysis Set)Time frame: The last 2 weeks of the expected 6-week treatment period.

Locations

42 sites in 14 countries. Site status is shown where the registry gives one.

  • AT004

    Vienna, Austria

  • BE005

    Brussels, Belgium

  • BE002

    Ottignies, Belgium

  • BE001

    Sint-Niklaas, Belgium

  • BG001

    Shumen, Bulgaria

  • BG008

    Sofia, Bulgaria

  • BG003

    Sofia, Bulgaria

  • BG006

    Sofia, Bulgaria

  • BG007

    Sofia, Bulgaria

  • BG004

    Varna, Bulgaria

  • BG005

    Vratsa, Bulgaria

  • CL005

    Temuco, Chile

  • HR001

    Zagreb, Croatia

  • DK006

    Aalborg, Denmark

  • DK004

    Herlev, Denmark

  • DE008

    Böhlen, Germany

  • DE010

    München, Germany

  • HU004

    Gyula, Hungary

  • HU002

    Miskolc, Hungary

  • HU011

    Nyíregyháza, Hungary

  • PL012

    Będzin, Poland

  • PL008

    Bydgoszcz, Poland

  • PL013

    Chorzów, Poland

  • PL014

    Dąbrowa Górnicza, Poland

  • PL003

    Gdansk, Poland

  • PL010

    Gliwice, Poland

  • PL015

    Warsaw, Poland

  • PL002

    Włocławek, Poland

  • RO001

    Brasov, Romania

  • RO002

    Cluj-Napoca, Romania

  • RO009

    Constanța, Romania

  • RO011

    Craiova, Romania

  • RS001

    Belgrade, Serbia

  • RS003

    Belgrade, Serbia

  • RS002

    Kamenitz, Serbia

  • RS005

    Zrenjanin, Serbia

  • SK007

    Bratislava, Slovakia

  • SK004

    Bratislava, Slovakia

  • SK001

    Prešov, Slovakia

  • SK005

    Pruské, Slovakia

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.